University of California San Francisco

Eric Nakakura
Eric Nakakura, MD, PhD

Professor of Surgery   
Division of Surgical Oncology

Address

550 16th Street, #6415
San Francisco, CA 94158
United States

Email: [email protected]
Fax: 415-353-9695

Biography

Dr. Eric Nakakura is a gastrointestinal cancer surgeon who specializes in tumors of the pancreas, bile ducts, liver, and GI tract. He also treats soft tissue sarcomas, including tumors of the retroperitoneum, trunk and extremities. Dr. Nakakura is a leading authority on neuroendocrine carcinoid tumors of the gastrointestinal tract and pancreas. In 2017, he was awarded a $1.2m grant from the Neuroendocrine Tumor Research Foundation (NETRF) to elucidate the causes of small intestinal neuroendocrine tumors (SI-NETs).

Dr. Nakakura earned a medical degree at Stanford Medical School and a doctorate degree in cellular and molecular medicine at the Johns Hopkins University. He completed a residency in general surgery at the Johns Hopkins Medical Institutions and was a specialist registrar in surgery at the John Radcliffe Hospital in Oxford, England. He also completed a fellowship in surgical oncology at the Johns Hopkins Medical Institutions.

Neuroendocrine tumors (NETs) of the small intestine and pancreas frequently spread throughout the body (i.e., metastasize). Surgery is often not possible for patients with advanced disease, and current therapies are ineffective for shrinking tumors and durable palliation of debilitating symptoms, often caused by the release of hormones into the blood. Dr. Nakakura and his colleagues' long-term goal is to find the causes of NETs of the small intestine and pancreas, which can lead to earlier diagnosis and ultimately a cure.

Videos

Education

Institution Degree Dept or School End Date
Stanford University M.D. School of Medicine 1995

Board Certifications

  • American Board of Surgery, 2004

Clinical Expertise

Ampullary Cancer

Bile Duct Cancer (Cholangiocarcinoma)

Borderline Resectable Pancreatic Cancer (BRPC)

Chronic Pancreatitis

Gallbladder Cancer

Gastrointestinal Neuroendocrine (Carcinoid) Tumors

Gastrointestinal Stromal Tumor (GIST)

Liver Cancer (Hepatocellular Carcinoma)

Liver Cysts

Liver Metastases

Pancreatic Cancer

Pancreatic Neuroendocrine (Islet Cell) Tumors

Pancreatic Pseudocysts

Retroperitoneal Neoplasms

Small Intestine Cancer

Soft Tissue Sarcoma

Stomach (Gastric) Cancer

Whipple Procedure (Pancreaticoduodenectomy)

Program Affiliations

  • GI Oncology Program
  • Member, UCSF Helen Diller Family Comprehensive Cancer Center
  • Surgical Oncology Laboratory
  • Sarcoma Program at UCSF

In the News

Eric Nakakura and Research Group Awarded $1.2M Grant to Study Small Intestinal Neuroendocrine Tumors
June, 03, 2017 | UCSF Surgical Oncology Program
Eric Nakakura and Emily Bergsland Discuss Carcinoid Syndrome Treatment on "Healthy Body, Healthy Mind" Series
January, 03, 2017 | UCSF Surgical Oncology Program
Surgery Now a Realistic Option for More Patients with Pancreatic Cancer
September, 10, 2016 | UCSF Surgical Oncology Program
Advancing the Treatment of Soft Tissue Sarcomas
July, 28, 2016 | UCSF Thoracic Oncology Program
CFCF Awards New Research Grant to Dr. Eric Nakakura to Study Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors
December, 13, 2012 | UCSF Surgical Oncology Program
Serendipitous Discovery of a Cancer Starter
December, 08, 2010 | UCSF Surgical Oncology Program
UCSF Scientists Illuminate How microRNAs Drive Tumor Progression
September, 16, 2009 | UCSF Surgical Oncology Program
Surgical & Therapeutic Advances in Pancreatic Cancer
July, 15, 2009 | UCSF Surgical Oncology Program

Research Narrative

Neuroendocrine tumors (NETs) of the small intestine and pancreas frequently spread throughout the body (i.e., metastasize). Surgery is often not possible for patients with advanced disease, and current therapies are ineffective for shrinking tumors and durable palliation of debilitating symptoms, often caused by the release of hormones into the blood. Dr. Nakakura and his colleagues’ long-term goal is to find the causes of NETs of the small intestine and pancreas, which can lead to earlier diagnosis and ultimately a cure.

How And Why Neuroendocrine Tumors Develop

In collaboration with Matthew Meyerson (Broad Institute, Dana-Farber Cancer Institute) and Chrissie Thirwell ( University College London Cancer Institute), Dr. Nakakura is studying the causes of small intestine neuroendocrine tumors utilizing state-of-the art genetic and epigenetic technologies of primary tumors and single cell analyses of precursor lesions. 

Funding: Neuroendocrine Tumor Research Foundation (NETRF) Accelerator Grant

Novel Neuroendocrine Tumor Models

A particular interest and focus of Dr. Nakakura’s translational research is the development of novel neuroendocrine tumor models.  His laboratory successfully developed a patient-derived pancreatic neuroendocrine tumor (PNETs) xenograft model--the onlysuch model in the world--that faithfully retains the pathologic and genetic aberrations typical of human PNETs.  Dr. Nakakura’s laboratory is collaborating with investigators worldwide, studying mechanisms of resistance to current therapies, novel small molecule targeted therapies, CAR T cell therapy, peptide receptor radionucleotide therapy, and the unfolded protein response. 

Funding: Neuroendocrine Tumor Research Foundation (NETRF), American Association for Cancer Research (AACR) 

Identification of Regulators of NET growth and Hormone Production

Dr. Nakakura’s laboratory has a long-term interest to elucidate the transcriptional and signaling events critical to the pathogenesis of NETs of the small intestine and pancreas, which can identify novel targets for diagnosis and treatment. His approach has been to turn to developmental biology for clues.  Dr. Nakakura and collegues have found that the same transcription factors (Ascl1, Nkx2.2, Fev, Scratch)1-4 and signaling pathways (Notch)2 that function in the normal development of endocrine cells throughout the body also act to regulate NET hormone production and growth, as well as metastasis.  These findings that conserved pathways of neuroendocrine differentiation function in cancer have also shed important insight into normal gut endocrine cell development. 

1 Nakakura EK, Watkins DN, Schuebel KE, Sriuranpong V, Borges MW, Nelkin BD, Ball DW. Mammalian Scratch: a neural-specific Snail family transcriptional repressor. Proc Natl Acad Sci U S A, Mar/27/2001;98(7):4010-5. PMID: 11274425 

2  Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M, Hsiao EC, Schuebel KE, Borges MW, Jin N, Collins BJ, Nelkin BD, Chen H, Ball DW. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by Notch signaling. J Clin Endocrinol Metab, Jul/2005;90(7):4350-6.  PMID: 15870121  

3  Wang YC, Gallego-Arteche E, Iezza G, Yuan X, Matli MR, Choo SP, Zuraek MB, Gogia R, Lynn FC, German MS, Bergsland EK, Donner DB, Warren RS, Nakakura EK. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors. Endocr Relat Cancer, Mar/2009;16(1):267-79.  PMID: 18987169 

4  Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland EK, Donner DB, Warren RS, Nakakura EK. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine. Endocr Relat Cancer, 2010;17(1):283-91.  PMID: 20048018 

Neuroendocrine Tumors of Unknown Primary

Dr. Nakakura and colleagues have found a straightforward solution to a challenging issue for patients with NETs.  Often patients are diagnosed with a NET; however, the primary site remains elusive.  Based on the small size, submucosal location, and outward growth pattern of ileum NETs, they hypothesized that most patients with NET of unknown primary tumor have an ileal primary tumor.1  Indeed, despite a negative preoperative evaluation, surgical exploration identifies an ileal primary tumor in most cases.1-3  Their studies show that the routine use of many other tests, such as capsule endoscopy, enteroclysis, double-balloon enteroscopy, and endoscopic ultrasonography, is unnecessary because they will not affect patient care and will only delay treatment. 

1 Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010 Mar; 145(3):276-80. PMID: 20231629 

2 Wang SC, Fidelman N, Nakakura EK. Management of well-differentiated gastrointestinal neuroendocrine tumors metastatic to the liver. Seminars in Oncology. 2013 Feb; 40(1):69-74. PMID 23391114

3 Bergsland EK, Nakakura EK. Neuroendocrine tumors of unknown primary: Is the primary site really not known? JAMA Surg. 2014 Sep; 149(9):889-90. PMID: 25029597

Predictors of Lymph Node Metastases in Pancreatic Neuroendocrine Tumors

The significance of lymph node metastases in PNETs is controversial. Consequently, the role and extent of lymph node sampling in PNETs is not standardized.  Therefore, there is no consensus regarding the optimal surgical approach for PNETs.  Surgical options include pancreas-preserving procedures (enucleation, central pancreatectomy) versus standard resections (pancreaticoduodenectomy, distal pancreatectomy). 

Dr. Nakakura and colleagues hypothesized that the conflicting prognostic value of PNET lymph node metastasis might be due to inadequate evaluations of lymph nodes and difficulties predicting metastasis.  They found that lymph nodes are not evaluated in many major pancreatic resections for PNET and preoperative prediction of nodal metastasis is difficult.1  Their findings suggest that enucleation of PNETs should be reserved for small insulinomas.  For other PNETs, surgeons should routinely sample lymph nodes, working closely with pathologists to maximize the number of lymph nodes identified in each specimen.  As a result of their study and that of others, the most recent NCCN guidelines for the management of PNETs have incorporated our recommendations and have affected patient management.2 

1 Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK. Lymph Node Sampling Rates and Predictors of Nodal Metastasis in Pancreatic Neuroendocrine Tumor Resections: The UCSF Experience With 149 Patients. Pancreas. 2012 Aug; 41(6):840-4.  PMID: 22781907  

2  http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf (login/password required)

Research Interests

  • Neuroendocrine (NE) tumors of the gastrointestinal (GI) Tract
  • The role of proendocrine transcription factors and signaling pathways in normal and neoplastic gut
  • Early detection of neuroendocrine tumors
  • Targeted therapy for treatment of neuroendocrine tumors
  • Concurrent EGFR and mTOR blockade in patients with pancreatic neuroendocrine tumors
  • Translational studies of cancers of the pancreas and gastrointestinal tract

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 109
  1. Factors associated with grade progression in pancreatic neuroendocrine tumors.
    Wang SJ, Kidder W, Joseph NM, Le BK, Lindsay S, Moon F, Nakakura EK, Zhang L, Bergsland EK| | PubMed
  2. Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer.
    Ejie J, Ashraf Ganjouei A, Hernandez S, Wang JJ, Romero-Hernandez F, Foroutani L, Hirose K, Nakakura E, Corvera CU, Alseidi A, Adam MA| | PubMed
  3. ASO Visual Abstract: Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma.
    Wong P, Pollini T, Adam MA, Alseidi A, Corvera CU, Hirose K, Kirkwood KS, Nakakura EK, Thornblade L, Maker AV| | PubMed
  4. Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC).
    Yin H, Romero-Hernandez F, Ganjouei AA, Wang JJ, Brown A, Hirose K, Maker AV, Nakakura E, Corvera C, Kirkwood KS, Wilhelm A, Peng JS, Alseidi A, Adam MA| | PubMed
  5. Graft choice in pancreatectomy with vascular resection: equivalent safety in selected patients.
    Hoffman D, Ganjouei AA, Hernandez FR, Ifuku K, Miller P, Glencer A, Corvera C, Kirkwood K, Alseidi A, Adam M, Maker A, Hirose K, Hirose R, Nakakura EK| | PubMed
  6. ASO Visual Abstract: Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
    Miller PN, Romero-Hernandez F, Calthorpe L, Wang JJ, Kim SS, Corvera CU, Hirose K, Kirkwood KS, Hirose R, Maker AV, Alseidi AA, Adam MA, Kim GE, Tempero MA, Ko AH, Nakakura EK| | PubMed
  7. Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma.
    Wong P, Pollini T, Adam MA, Alseidi A, Corvera CU, Hirose K, Kirkwood KS, Nakakura EK, Thornblade L, Maker AV| | PubMed
  8. Enucleation of Neuroendocrine Liver Metastases.
    Yogo A, Kasai Y, Nakakura EK| | PubMed
  9. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
    Parikh AR, Chee BH, Tsai J, Rich TA, Price KS, Patel SA, Zhang L, Ibrahim F, Esquivel M, Van Seventer EE, Jarnagin JX, Raymond VM, Corvera CU, Hirose K, Nakakura EK, Corcoran RB, Van Loon K, Atreya CE| | PubMed
  10. ASO Author Reflections: Total Neoadjuvant Therapy with Chemotherapy Alone for Pancreatic Cancer?
    Miller PN, Nakakura EK| | PubMed
109
View all 109 Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 109
  1. Factors associated with grade progression in pancreatic neuroendocrine tumors.
    Wang SJ, Kidder W, Joseph NM, Le BK, Lindsay S, Moon F, Nakakura EK, Zhang L, Bergsland EK| | PubMed
  2. Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer.
    Ejie J, Ashraf Ganjouei A, Hernandez S, Wang JJ, Romero-Hernandez F, Foroutani L, Hirose K, Nakakura E, Corvera CU, Alseidi A, Adam MA| | PubMed
  3. ASO Visual Abstract: Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma.
    Wong P, Pollini T, Adam MA, Alseidi A, Corvera CU, Hirose K, Kirkwood KS, Nakakura EK, Thornblade L, Maker AV| | PubMed
  4. Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC).
    Yin H, Romero-Hernandez F, Ganjouei AA, Wang JJ, Brown A, Hirose K, Maker AV, Nakakura E, Corvera C, Kirkwood KS, Wilhelm A, Peng JS, Alseidi A, Adam MA| | PubMed
  5. Graft choice in pancreatectomy with vascular resection: equivalent safety in selected patients.
    Hoffman D, Ganjouei AA, Hernandez FR, Ifuku K, Miller P, Glencer A, Corvera C, Kirkwood K, Alseidi A, Adam M, Maker A, Hirose K, Hirose R, Nakakura EK| | PubMed
  6. ASO Visual Abstract: Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
    Miller PN, Romero-Hernandez F, Calthorpe L, Wang JJ, Kim SS, Corvera CU, Hirose K, Kirkwood KS, Hirose R, Maker AV, Alseidi AA, Adam MA, Kim GE, Tempero MA, Ko AH, Nakakura EK| | PubMed
  7. Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma.
    Wong P, Pollini T, Adam MA, Alseidi A, Corvera CU, Hirose K, Kirkwood KS, Nakakura EK, Thornblade L, Maker AV| | PubMed
  8. Enucleation of Neuroendocrine Liver Metastases.
    Yogo A, Kasai Y, Nakakura EK| | PubMed
  9. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
    Parikh AR, Chee BH, Tsai J, Rich TA, Price KS, Patel SA, Zhang L, Ibrahim F, Esquivel M, Van Seventer EE, Jarnagin JX, Raymond VM, Corvera CU, Hirose K, Nakakura EK, Corcoran RB, Van Loon K, Atreya CE| | PubMed
  10. ASO Author Reflections: Total Neoadjuvant Therapy with Chemotherapy Alone for Pancreatic Cancer?
    Miller PN, Nakakura EK| | PubMed
  11. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
    Miller PN, Romero-Hernandez F, Calthorpe L, Wang JJ, Kim SS, Corvera CU, Hirose K, Kirkwood KS, Hirose R, Maker AV, Alseidi AA, Adam MA, Kim GE, Tempero MA, Ko AH, Nakakura EK| | PubMed
  12. ASO Author Reflections: Minimally Invasive Surgery for Prototypical Small Intestinal Neuroendocrine Tumors.
    Yogo A, Nakakura EK| | PubMed
  13. Long-Term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
    Yogo A, Paciorek A, Kasai Y, Moon F, Hirose K, Corvera CU, Bergsland EK, Nakakura EK| | PubMed
  14. National practice patterns in the use of endoscopic ultrasound biopsy for resectable Pancreatic Neuroendocrine Tumors: Insights into the role of DOTATATE PET/CT in diagnosis.
    Casey M, Brown A, Romero-Hernandez F, Wang JJ, Ganjouei AA, Tozzi F, Rashidian N, Kirkwood K, Corvera C, Nakakura E, Alseidi A, Adam M| | PubMed
  15. Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors.
    Wong P, Wisneski AD, Tsai KK, Chang TT, Hirose K, Nakakura EK, Daud AI, Maker AV, Corvera CU| | PubMed
  16. Robotic-assisted endoluminal gastric leiomyoma resection: a novel surgical technique for benign gastroesophageal junction tumors.
    Yin H, Ganjouei AA, Wang JJ, Romero-Hernandez F, Nakakura E, Alseidi A, Adam MA| | PubMed
  17. Improved survival of patients receiving immunotherapy and chemotherapy following curative-intent resection of colorectal liver metastases.
    Pollini T, Tran T, Wong P, Adam MA, Alseidi A, Corvera C, Hirose K, Nakakura E, Warren R, Maker VK, Maker AV| | PubMed
  18. A Machine Learning Approach to Predict Postoperative Pancreatic Fistula After Pancreaticoduodenectomy Using Only Preoperatively Known Data.
    Ashraf Ganjouei A, Romero-Hernandez F, Wang JJ, Casey M, Frye W, Hoffman D, Hirose K, Nakakura E, Corvera C, Maker AV, Kirkwood KS, Alseidi A, Adam MA| | PubMed
  19. ASO Visual Abstract: National Practice Patterns in Malignant Peritoneal Mesothelioma-Updates in Management and Survival.
    Calthorpe L, Romero-Hernandez F, Casey M, Nunez M, Conroy PC, Hirose K, Kim A, Kirkwood K, Maker AV, Corvera C, Nakakura E, Alseidi A, Adam MA| | PubMed
  20. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.
    Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA| | PubMed
  21. Residual Tumor Volume, Not Percent Cytoreduction, Matters for Surgery of Neuroendocrine Liver Metastasis.
    Kasai Y, Nakakura EK, Yogo A, Nagai K, Masui T, Hatano E| | PubMed
  22. Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
    Chiorean EG, Chiaro MD, Tempero MA, Malafa MP, Benson AB, Cardin DB, Christensen JA, Chung V, Czito B, Dillhoff M, Donahue TR, Dotan E, Fountzilas C, Glazer ES, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Masood A, Moravek C, Nakakura EK, Narang AK, Nardo L, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Truty MJ, Vollmer C, Wolff RA, Wolpin BM, Rn BM, Lubin S, Darlow SD| | PubMed
  23. National Practice Patterns in Malignant Peritoneal Mesothelioma: Updates in Management and Survival.
    Calthorpe L, Romero-Hernandez F, Casey M, Nunez M, Conroy PC, Hirose K, Kim A, Kirkwood K, Maker AV, Corvera C, Nakakura E, Alseidi A, Adam MA| | PubMed
  24. Laparoscopic Gastrectomy for Gastric Cancer.
    Hoffman DB, Nakakura EK| | PubMed
  25. Metastatic colorectal adenocarcinoma tumor purity assessment from whole exome sequencing data.
    Tbeileh N, Timmerman L, Mattis AN, Toriguchi K, Kasai Y, Corvera C, Nakakura E, Hirose K, Donner DB, Warren RS, Karelehto E| | PubMed
  26. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time.
    Wang SJ, Whitman J, Paciorek A, Le BK, Nakakura EK, Behr SC, Joseph N, Zhang L, Hope TA, Bergsland EK| | PubMed
  27. Hypertension Requiring Medication Use: a Silent Predictor of Poor Outcomes After Pancreaticoduodenectomy.
    Lin JJ, Conroy PC, Romero-Hernandez F, Yilma M, Feng J, Hirose K, Nakakura E, Maker AV, Corvera C, Kirkwood K, Alseidi A, Adam MA| | PubMed
  28. Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States.
    Calthorpe L, Romero-Hernandez F, Miller P, Conroy PC, Hirose K, Kim A, Kirkwood K, Nakakura E, Corvera C, Maker AV, Alseidi A, Adam MA| | PubMed
  29. Hand-Assisted Versus Pure Minimally-Invasive Distal Pancreatectomy: Is There a Downside to Lending a Hand?
    Miller PN, Romero-Hernandez F, Conroy P, Calthorpe L, Yilma M, Mohamedaly S, Kelly YM, Feng J, Hirose K, Kirkwood K, Maker AV, Corvera C, Nakakura E, Alseidi A, Adam MA| | PubMed
  30. Minimally Invasive Distal Pancreatectomy Techniques: A Contemporary Analysis Exploring Trends, Similarities, and Differences to Open Surgery.
    Romero-Hernandez F, Mohamedaly S, Miller P, Rodriguez N, Calthorpe L, Conroy PC, Ganjouei AA, Hirose K, Maker AV, Nakakura E, Corvera C, Kirkwood KS, Alseidi A, Adam MA| | PubMed
  31. Whole genome sequencing reveals the independent clonal origin of multifocal ileal neuroendocrine tumors.
    Mäkinen N, Zhou M, Zhang Z, Kasai Y, Perez E, Kim GE, Thirlwell C, Nakakura E, Meyerson M| | PubMed
  32. ASO Visual Abstract: Determining Hospital Volume Threshold for the Safety of Minimally Invasive Pancreaticoduodenectomy: A Contemporary Cutpoint Analysis.
    Conroy PC, Calthorpe L, Lin JA, Mohamedaly S, Kim A, Hirose K, Nakakura E, Corvera C, Sosa JA, Sarin A, Kirkwood KS, Alseidi A, Adam MA| | PubMed
  33. Optimal Staging for Gastric Cancer Starts With High-Resolution Computed Tomography.
    Brown AE, Nakakura EK| | PubMed
  34. Determining Hospital Volume Threshold for Safety of Minimally Invasive Pancreaticoduodenectomy: A Contemporary Cutpoint Analysis.
    Conroy PC, Calthorpe L, Lin JA, Mohamedaly S, Kim A, Hirose K, Nakakura E, Corvera C, Sosa JA, Sarin A, Kirkwood KS, Alseidi A, Adam MA| | PubMed
  35. Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study.
    Kasai Y, Masui T, Nakakura EK, Nakano K, Sato A, Uchida Y, Yogo A, Nagai K, Anazawa T, Hope TA, Kim GE, Whitman J, Le BK, Takaori K, Bergsland EK, Hatano E, Uemoto S| | PubMed
  36. Evidence-Based Guidelines for Branch-Duct Intraductal Papillary Mucinous Neoplasm Management: Still a Lot of Room to Grow.
    Conroy PC, Nakakura E| | PubMed
  37. Outcomes after high-dose radiation in the management of neuroendocrine neoplasms.
    Chen KS, Lawhn-Heath C, Behr S, Juarez R, Whitman J, Paciorek A, Nakakura EK, Fidelman N, Feng MU, Bergsland EK, Anwar M| | PubMed
  38. Burden of Ionizing Radiation in the Diagnosis and Management of Necrotizing Pancreatitis.
    Thiruvengadam NR, Miranda J, Kim C, Behr S, Corvera C, Dai SC, Kirkwood K, Harris HW, Hirose K, Nakakura E, Ostroff JW, Kochman ML, Arain MA| | PubMed
  39. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV| | PubMed
  40. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database.
    Chan H, Zhang L, Choti MA, Kulke M, Yao JC, Nakakura EK, Bloomston M, Benson AB, Shah MH, Strosberg JR, Bergsland EK, Van Loon K| | PubMed
  41. Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
    Mahuron KM, Kasai Y, Javeed ZA, Bergsland EK, Hirose K, Corvera CU, Nakakura EK| | PubMed
  42. Contemporary Management of Hepatic Cyst Disease: Techniques and Outcomes at a Tertiary Hepatobiliary Center.
    Gomez A, Wisneski AD, Luu HY, Hirose K, Roberts JP, Hirose R, Freise CE, Nakakura EK, Corvera CU| | PubMed
  43. Hybrid Low-Grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma of the Pancreas.
    Kramer SP, Bowman CJ, Wang ZJ, Sheahon KM, Nakakura EK, Cho SJ, Umetsu SE, Behr SC| | PubMed
  44. Randomized Clinical Trial of Nasogastric Tube Placement After Pancreaticoduodenectomy.
    Sharib JM, Nakakura EK| | PubMed
  45. Synchronous Versus Metachronous Colorectal Liver Metastasis Yields Similar Survival in Modern Era.
    Wisneski AD, Jin C, Huang CY, Warren R, Hirose K, Nakakura EK, Corvera CU| | PubMed
  46. Awareness of a mesenteric mass as a common manifestation of ileal neuroendocrine tumor.
    Kasai Y, Nakakura EK| | PubMed
  47. Patterns of chromosome 18 loss of heterozygosity in multifocal ileal neuroendocrine tumors.
    Zhang Z, Mäkinen N, Kasai Y, Kim GE, Diosdado B, Nakakura E, Meyerson M| | PubMed
  48. Ampullary stenosis and choledocholithiasis post Roux-En-Y gastric bypass: challenges of biliary access and intervention.
    Wisneski AD, Carter J, Nakakura EK, Posselt A, Rogers SJ, Cello JP, Arain M, Kirkwood KS, Hirose K, Stewart L, Corvera CU| | PubMed
  49. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.
    Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK| | PubMed
  50. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis.
    Kasai Y, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Harun N, Kim MO, Warren RS, Bergsland EK, Nakakura EK| | PubMed
  51. Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors.
    Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK| | PubMed
  52. Adjuvant Therapy for Ampullary Cancer.
    Ko AH, Nakakura EK| | PubMed
  53. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.
    Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS| | PubMed
  54. Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases.
    Kwon DH, Paciorek A, Mulvey CK, Chan H, Fidelman N, Meng L, Nakakura EK, Zhang L, Bergsland EK, Van Loon K| | PubMed
  55. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?
    Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE| | PubMed
  56. Pancreatic Adenocarcinoma, Version 1.2019.
    Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G| | PubMed
  57. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.
    Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS| | PubMed
  58. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK| | PubMed
  59. Outcomes of arterial bypass preceding resection of retroperitoneal masses involving major vessels.
    Luu HY, Wang ED, Syed SM, Xu X, Hansen SL, Eichler CM, Nakakura EK| | PubMed
  60. Progress in the March to Precision Cancer Medicine: Left, Right, Left.
    Nakakura EK| | PubMed
  61. Challenges Staging Neuroendocrine Tumors of the Pancreas, Jejunum and Ileum, and Appendix.
    Nakakura EK| | PubMed
  62. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
    Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S| | PubMed
  63. Gastrocutaneous Fistula in a Patient with Locally Recurrent MSI-High Colorectal Cancer: Local Complications Arising from Therapeutic Response to Immune Checkpoint Blockade.
    Greene C, Nakakura EK, Ko AH| | PubMed
  64. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.
    Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF| | PubMed
  65. Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1.
    Mulvey CK, Van Loon K, Bergsland EK, Masharani U, Nakakura EK| | PubMed
  66. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
    Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH| | PubMed
  67. Finding the Common Thread in Rare Diseases.
    Nakakura EK| | PubMed
  68. Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging.
    Hope TA, Verdin EF, Bergsland EK, Ohliger MA, Corvera CU, Nakakura EK| | PubMed
  69. Solid pseudopapillary neoplasm of the pancreas head in a pregnant woman: safe pancreaticoduodenectomy postpartum.
    Yee AM, Kelly BG, Gonzalez-Velez JM, Nakakura EK| | PubMed
  70. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
    Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E| | PubMed
  71. A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer.
    Walker EJ, Simko JP, Nakakura EK, Ko AH| | PubMed
  72. Bone metastases and skeletal-related events from neuroendocrine tumors.
    Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah MH, Bergsland EK| | PubMed
  73. Neuroendocrine tumors of unknown primary: is the primary site really not known?
    Bergsland EK, Nakakura EK| | PubMed
  74. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.
    Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA| | PubMed
  75. Time to put another surgical dogma to sleep?
    Nakakura EK| | PubMed
  76. Home, sweet home, after surgery.
    Nakakura EK| | PubMed
  77. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
    Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS| | PubMed
  78. Management of well-differentiated gastrointestinal neuroendocrine tumors metastatic to the liver.
    Wang SC, Fidelman N, Nakakura EK| | PubMed
  79. Reply to P.H. Sugarbaker.
    Nakakura EK| | PubMed
  80. Can CT features differentiate between inferior vena cava leiomyosarcomas and primary retroperitoneal masses?
    Webb EM, Wang ZJ, Westphalen AC, Nakakura EK, Coakley FV, Yeh BM| | PubMed
  81. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
    Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK| | PubMed
  82. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
    Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA, National Comprehensive Cancer Networks| | PubMed
  83. Pseudomyxoma peritonei: more questions than answers.
    Nakakura EK| | PubMed
  84. Complete and safe resection of challenging retroperitoneal tumors: anticipation of multi-organ and major vascular resection and use of adjunct procedures.
    Tseng WW, Wang SC, Eichler CM, Warren RS, Nakakura EK| | PubMed
  85. Unique patterns of metastases in common and rare types of malignancy.
    Leong SP, Nakakura EK, Pollock R, Choti MA, Morton DL, Henner WD, Lal A, Pillai R, Clark OH, Cady B| | PubMed
  86. Pancreatic adenocarcinoma.
    Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW, Malafa MP, Muscarella P, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA, NCCN Pancreatic Adenocarcinoma| | PubMed
  87. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.
    Wang YC, Iezza G, Zuraek MB, Jablons DM, Theodore PR, Bergsland EK, Donner DB, Warren RS, Nakakura EK| | PubMed
  88. Arterial embolization for the management of gastrointestinal hemorrhage from metastatic renal cell carcinoma.
    Fidelman N, Freed RC, Nakakura EK, Rosenberg J, Bloom AI| | PubMed
  89. Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
    Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK| | PubMed
  90. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine.
    Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland EK, Donner DB, Warren RS, Nakakura EK| | PubMed
  91. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer.
    Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, Libutti SK, Nakakura EK, Golub TR, Hanahan D| | PubMed
  92. Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers.
    Ruan DT, Warren RS, Moalem J, Chung KW, Griffin AC, Shen W, Duh QY, Nakakura E, Donner DB, Khanafshar E, Weng J, Clark OH, Kebebew E| | PubMed
  93. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.
    Wang YC, Gallego-Arteche E, Iezza G, Yuan X, Matli MR, Choo SP, Zuraek MB, Gogia R, Lynn FC, German MS, Bergsland EK, Donner DB, Warren RS, Nakakura EK| | PubMed
  94. Compound muscle action potentials and spontaneous electromyography can be used to identify and protect the femoral nerve during resection of large retroperitoneal tumors.
    Guo L, Clark JP, Warren RS, Nakakura EK| | PubMed
  95. Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas.
    Horvai AE, Schaefer JT, Nakakura EK, O'Donnell RJ| | PubMed
  96. Introduction.
    Warren RS, Nakakura EK| | PubMed
  97. Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology.
    Tempero M, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, Kim P, Malafa MP, Nakakura EK, Shibata S, Talamonti M, Wang H, Willett C| | PubMed
  98. Palliative care for patients with advanced pancreatic and biliary cancers.
    Nakakura EK, Warren RS| | PubMed
  99. Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?
    Nakakura EK, Venook AP, Bergsland EK| | PubMed
  100. Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region.
    Nakakura EK, Bergsland EK| | PubMed
  101. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.
    Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, Ball DW, Nelkin BD| | PubMed
  102. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling.
    Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M, Hsiao EC, Schuebel KE, Borges MW, Jin N, Collins BJ, Nelkin BD, Chen H, Ball DW| | PubMed
  103. Notch signaling induces rapid degradation of achaete-scute homolog 1.
    Sriuranpong V, Borges MW, Strock CL, Nakakura EK, Watkins DN, Blaumueller CM, Nelkin BD, Ball DW| | PubMed
  104. Mammalian Scratch participates in neuronal differentiation in P19 embryonal carcinoma cells.
    Nakakura EK, Watkins DN, Sriuranpong V, Borges MW, Nelkin BD, Ball DW| | PubMed
  105. Mammalian Scratch: a neural-specific Snail family transcriptional repressor.
    Nakakura EK, Watkins DN, Schuebel KE, Sriuranpong V, Borges MW, Nelkin BD, Ball DW| | PubMed
  106. Management of hepatocellular carcinoma.
    Nakakura EK, Choti MA| | PubMed
  107. Long-term survival of solid organ allografts by brief anti-lymphocyte function-associated antigen-1 monoclonal antibody monotherapy.
    Nakakura EK, Shorthouse RA, Zheng B, McCabe SM, Jardieu PM, Morris RE| | PubMed
  108. A non-lymphocyte-depleting monoclonal antibody to the adhesion molecule LFA-1 (CD11a) prevents sensitization to alloantigens and effectively prolongs the survival of heart allografts.
    Nakakura EK, McCabe SM, Zheng B, Shorthouse RA, Scheiner TM, Blank G, Jardieu PM, Morris RE| | PubMed
  109. Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of non-primarily vascularized heart allograft survival in mice without T cell depletion.
    Nakakura EK, McCabe SM, Zheng B, Shorthouse RA, Scheiner TM, Blank G, Jardieu PM, Morris RE| | PubMed